Skip to main content
DaehanPharmaceutical logo

DaehanPharmaceutical — Investor Relations & Filings

Ticker · 023910 ISIN · KR7023910003 KO Manufacturing
Open in API
Filings indexed 297 across all filing types
Latest filing 2022-02-25 Proxy Solicitation & In…
Country KR South Korea
Listing KO 023910

About DaehanPharmaceutical

https://www.dhnp.co.kr/

Daehan Nupharm is a pharmaceutical company engaged in the research, development, and manufacturing of a diverse portfolio of healthcare products. The company's business is structured around four core areas: human pharmaceuticals, offering a range of therapeutic treatments; animal health products for both companion and livestock animals; advanced bio-pharmaceuticals, with a focus on next-generation technologies like cell therapy; and health functional foods. Established initially in the animal health sector, the company leverages its dedicated Central and Bio Research Institutes to drive innovation and develop solutions for global markets. The R&D efforts concentrate on strengthening technological capabilities and advancing new treatment modalities.

Recent filings

Filing Released Lang Actions
주주총회소집공고
Proxy Solicitation & Information Statement Classification · 1% confidence The document is a 'Notice of Convocation of the Annual General Meeting' (주주총회소집공고) for Daihan Pharm Co., Ltd. It contains the meeting agenda, details on voting procedures (including electronic voting), and management's reference materials (business overview, financial statements, and audit information) required by law to be provided to shareholders prior to the meeting. This document is a standard Proxy Solicitation & Information Statement (PSI) used to inform shareholders and request their votes for the upcoming AGM.
2022-02-25 Korean
의결권대리행사권유참고서류
Proxy Solicitation & Information Statement Classification · 1% confidence The document is titled '의결권대리행사권유참고서류' (Proxy Solicitation Reference Document) and contains detailed information regarding the upcoming Annual General Meeting (AGM), including the agenda, voting procedures, and proxy solicitation details. It also includes financial statements as part of the meeting materials. This is a standard proxy solicitation document used to request shareholder votes for an AGM.
2022-02-25 Korean
주주총회소집결의
AGM Information Classification · 1% confidence The document is a formal notice of a General Meeting of Shareholders (주주총회소집결의) for Daehan Pharmaceutical. It outlines the date, location, and agenda items (such as approval of financial statements, articles of incorporation changes, and director compensation). This type of document is a standard proxy solicitation/notice of meeting, which falls under the Proxy Solicitation & Information Statement category.
2022-02-17 Korean
매출액또는손익구조30%(대규모법인은15%)이상변동
Earnings Release Classification · 1% confidence The document is a regulatory filing from a Korean company (Daehan Pharmaceutical) disclosing a significant change in financial structure (revenue or profit/loss fluctuation of 30% or more). This is a standard regulatory disclosure requirement in the Korean market (KRX) for material financial events. It provides specific financial data and reasons for the change, fitting the definition of a regulatory filing (RNS) as it does not constitute a full annual report or a simple announcement of a report's publication. FY 2021
2022-02-09 Korean
현금ㆍ현물배당결정
Notice of Dividend Amount Classification · 1% confidence The document is a formal announcement from '대한약품' (Daehan Pharm) regarding a decision on cash dividends. It specifies the dividend amount per share, the dividend record date, and the board approval date. This falls directly under the definition of a dividend announcement.
2022-02-09 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 1% confidence The document is a 'Report on Ownership of Specific Securities by Executives and Major Shareholders' (임원ㆍ주요주주 특정증권등 소유상황보고서). This is a standard regulatory filing in South Korea (DART system) used to disclose insider trading or changes in shareholdings by company directors and major shareholders. This corresponds to the 'Director's Dealing' category.
2022-01-27 Korean

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.